JPET xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Miller, D. K.
Right arrow Articles by Dwoskin, L. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Miller, D. K.
Right arrow Articles by Dwoskin, L. P.

Vol. 302, Issue 3, 1113-1122, September 2002

Bupropion Inhibits Nicotine-Evoked [3H]Overflow from Rat Striatal Slices Preloaded with [3H]Dopamine and from Rat Hippocampal Slices Preloaded with [3H]Norepinephrine

Dennis K. Miller, Sangeetha P. Sumithran and Linda P. Dwoskin

College of Pharmacy, University of Kentucky, Lexington, Kentucky

Bupropion, an efficacious antidepressant and smoking cessation agent, inhibits dopamine and norepinephrine transporters (DAT and NET, respectively). Recently, bupropion has been reported to noncompetitively inhibit alpha 3beta 2, alpha 3beta 4, and alpha 4beta 2 nicotinic acetylcholine receptors (nAChRs) expressed in Xenopus oocytes or established cell lines. The present study evaluated bupropion-induced inhibition of native alpha 3beta 2* and alpha 3beta 4* nAChRs using functional neurotransmitter release assays, nicotine-evoked [3H]overflow from superfused rat striatal slices preloaded with [3H]dopamine ([3H]DA), and nicotine-evoked [3H]overflow from hippocampal slices preloaded with [3H]norepinephrine ([3H]NE). The mechanism of inhibition was evaluated using Schild analysis. To eliminate the interaction of bupropion with DAT or NET, nomifensine or desipramine, respectively, was included in the superfusion buffer. A high bupropion concentration (100 µM) elicited intrinsic activity in the [3H]DA release assay. However, none of the concentrations (1 nM-100 µM) examined evoked [3H]NE overflow and, thus, were without intrinsic activity in this assay. Moreover, bupropion inhibited both nicotine-evoked [3H]DA overflow (IC50 = 1.27 µM) and nicotine-evoked [3H]NE overflow (IC50 = 323 nM) at bupropion concentrations well below those eliciting intrinsic activity. Results from Schild analyses suggest that bupropion competitively inhibits nicotine-evoked [3H]DA overflow, whereas evidence for receptor reserve was obtained upon assessment of bupropion inhibition of nicotine-evoked [3H]NE overflow. Thus, bupropion acts as an antagonist at alpha 3beta 2* and alpha 3beta 4* nAChRs in rat striatum and hippocampus, respectively, across the same concentration range that inhibits DAT and NET function. The combination of nAChR and transporter inhibition produced by bupropion may contribute to its clinical efficacy as a smoking cessation agent.

0022-3565/02/3023-1113$07.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 2002 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 J. Pharmacol. Exp. Ther.Home page
P. R. Lockman, V. K. Manda, W. J. Geldenhuys, R. K. Mittapalli, F. Thomas, Z. F. Albayati, P. A. Crooks, L. P. Dwoskin, and D. D. Allen
Carrier-Mediated Transport of the Quaternary Ammonium Neuronal Nicotinic Receptor Antagonist N,N'-Dodecylbispicolinium Dibromide at the Blood-Brain Barrier
J. Pharmacol. Exp. Ther., January 1, 2008; 324(1): 244 - 250.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
M. Alkondon and E. X. Albuquerque
Nicotinic Receptor Subtypes in Rat Hippocampal Slices Are Differentially Sensitive to Desensitization and Early in Vivo Functional Up-Regulation by Nicotine and to Block by Bupropion
J. Pharmacol. Exp. Ther., May 1, 2005; 313(2): 740 - 750.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
M. E. Myles, A. M. Azcuy, N. T. Nguyen, E. R. Reisch, S. A. Barker, H. W. Thompson, and J. M. Hill
Bupropion (Zyban, Wellbutrin) Inhibits Nicotine-Induced Viral Reactivation in Herpes Simplex Virus Type 1 Latent Rabbits
J. Pharmacol. Exp. Ther., November 1, 2004; 311(2): 640 - 644.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
M. I. Damaj, F. I. Carroll, J. B. Eaton, H. A. Navarro, B. E. Blough, S. Mirza, R. J. Lukas, and B. R. Martin
Enantioselective Effects of Hydroxy Metabolites of Bupropion on Behavior and on Function of Monoamine Transporters and Nicotinic Receptors
Mol. Pharmacol., September 1, 2004; 66(3): 675 - 682.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
L. S. Middleton, W. A. Cass, and L. P. Dwoskin
Nicotinic Receptor Modulation of Dopamine Transporter Function in Rat Striatum and Medial Prefrontal Cortex
J. Pharmacol. Exp. Ther., January 1, 2004; 308(1): 367 - 377.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
A. S. Rauhut, S. N. Mullins, L. P. Dwoskin, and M. T. Bardo
Reboxetine: Attenuation of Intravenous Nicotine Self-Administration in Rats
J. Pharmacol. Exp. Ther., November 1, 2002; 303(2): 664 - 672.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2002 by the American Society for Pharmacology and Experimental Therapeutics.